Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma.
The incipient development of gene therapy for cancer has fuelled its progression from bench to bedside in mere decades. Of all malignancies that exist, gliomas are the largest class of brain tumors, and are renowned for their aggressiveness and resistance to therapy. In order for gene therapy to achieve clinical success, a multitude of barriers ranging from glioma tumor physiology to vector biology must be overcome. Many viral gene delivery systems have been subjected to clinical investigation; however, with highly limited success. In this review, the current progress and challenges of gene therapy for malignant glioma are discussed. Moreover, we highlight the hybrid adeno-associated virus and bacteriophage vector as a potential candidate for targeted gene delivery to brain tumors.
Phage Therapy Group, Department of Medicine, Imperial College London, Burlington Danes Building, Hammersmith Hospital, Du Cane Road, London, UK.
Paladd
P
Asavarut
Kevin
K
O'Neill
Nelofer
N
Syed
Amin
A
Hajitou
D000818:Animals; D001435:Bacteriophages / Q000235:genetics*; D001812:Blood-Brain Barrier / Q000378:metabolism; D001932:Brain Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D002199:Capillary Permeability; D000229:Dependovirus / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D005910:Glioma / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D006801:Humans; D000067492:RNAi Therapeutics